Showing results (271-280 of 277) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 277 results.
Targeted Oncology|April 30, 2024
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus BevacizumabMara Persano, Margherita Rimini, Toshifumi Tada, et al.
Targeted Oncology|January 22, 2024
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular CarcinomaSilvia Camera, Margherita Rimini, Federico Rossari, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2023
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patientsMara Persano, Margherita Rimini, Toshifumi Tada, et al.
Oncology|October 13, 2024
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World StudyMara Persano, Andrea Casadei-Gardini, Toshifumi Tada, et al.
Liver Cancer|September 19, 2024
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter StudyFederico Rossari, Toshifumi Tada, Goki Suda, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 22, 2024
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumabMargherita Rimini, Bernardo Stefanini, Toshifumi Tada, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2022
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide populationAndrea Casadei-Gardini, Margherita Rimini, Toshifumi Tada, et al.
Pageof 28